Skip to content
POM-V Prescription Required

Equip FT Suspension for Injection

Active ingredients: Equine influenza virus, Tetanus toxoid, immunopurified (IPTT)

Form

Injection

Species

Horses

Manufacturer

Zoetis Belgium S.A.

VMD MA No.

60021/3010

What it's used for

Onset of immunity: within 2 weeks of completion of the primary course. Duration of immunity: 1 year and 3 months for influenza and 3 years for tetanus.

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Equine influenza virus + Tet...

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Equip FT Suspension for Injection — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Onset of immunity: within 2 weeks of completion of the primary course.
Duration of immunity: 1 year and 3 months for influenza and 3 years for tetanus.
Vaccination schedule:
medicinal product should be used as follows:
Primary course
6 week interval
Second dose EQUIP FT
5 month interval
Boosters
12-15 month interval
2nd booster EQUIP F
12-15 month interval
3rd booster EQUIP FT
Thereafter, booster doses of Equip FT or Equip F should be administered so that the interval
between vaccinations against influenza is no more than 15 months and the interval between
vaccinations against tetanus is not more than 36 months.
Note: The routine practice of administering booster doses against influenza annually may
remain the most convenient, even though protection against equine influenza has been
demonstrated by challenge studies 15 months following the third vaccination (first booster
dose). No field challenge studies have been carried out prior to the third vaccination; instead,
efficacy was evaluated by serology which showed titres equivalent to those found in horses
protected against challenge at 15 months. It is recommended that a single booster dose
should only be administered to horses that have already received a full primary course using
vaccines that contain the same types of equine influenza virus included in this vaccine. A full
primary course may be considered necessary in horses that have not been suitably primed.
None.
Horses:
Rare
(1 to 10 animals / 10,000 animals treated):
Injection site swelling
1,3
Stiffness
Elevated temperature
1,2
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Injection site pain
Hypersensitivity reaction
Anorexia, Lethargy
This condition normally resolves by the day following vaccination.
Mild, transient, typically 9-12 hours post vaccination.
Local, small (10-20 mm in diameter), soft, non-painful.
In the event of an allergic or anaphylactic reaction, immediate treatment should be given
with a soluble glucocorticoid intravenously or adrenalin intramuscularly.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary
medicinal product. Reports should be sent, preferably via a veterinarian, to either the
marketing authorisation holder or the national competent authority via the national reporting
system. See the package leaflet for respective contact details.
Vaccinate healthy animals only.
The efficacy of active immunisation of young foals against equine influenza and tetanus will
be influenced by the level of maternally derived antibodies. This will vary between individuals
due to a number of factors, e.g. the immune status of the dam; adequacy of colostrum intake
by the foal, etc. The vaccine should not be used in foals below 5 months of age, and foals
should not be vaccinated until maternally derived antibodies have fallen below protective
levels.
In any animal population, there may be a small number of individuals which fail to respond
fully to vaccination. Successful vaccination depends upon correct storage and administration
of the vaccine and the ability of the animal to respond. This can be influenced by such factors
as genetic constitution, intercurrent infection, age, nutritional status, concurrent drug therapy
and stress.

Special precautions for safe use in the target species:
Not applicable.
Special precautions to be taken by the person administering the veterinary medicinal product
to animals:
In case of accidental self-injection, seek medical advice immediately and show the package
leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.
No information is available on the safety and efficacy of this vaccine when used with any other
veterinary medicinal product. A decision to use this vaccine before or after any other
veterinary medicinal product therefore needs to be made on a case-by-case basis.
Store in a refrigerator (2 C – 8 C).
Protect from light. Do not freeze.
Keep the container in the outer carton.
Zero days.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.